Annual Cash & Cash Equivalents
$88.20 M
-$51.05 M-36.66%
December 31, 2023
Summary
- As of February 12, 2025, AGIO annual cash & cash equivalents is $88.20 million, with the most recent change of -$51.05 million (-36.66%) on December 31, 2023.
- During the last 3 years, AGIO annual cash & cash equivalents has fallen by -$39.23 million (-30.78%).
- AGIO annual cash & cash equivalents is now -56.58% below its all-time high of $203.13 million, reached on December 31, 2021.
Performance
AGIO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$253.73 M
+$169.21 M+200.21%
September 30, 2024
Summary
- As of February 12, 2025, AGIO quarterly cash and cash equivalents is $253.73 million, with the most recent change of +$169.21 million (+200.21%) on September 30, 2024.
- Over the past year, AGIO quarterly cash and cash equivalents has increased by +$169.21 million (+200.21%).
- AGIO quarterly cash and cash equivalents is now -86.56% below its all-time high of $1.89 billion, reached on March 31, 2021.
Performance
AGIO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AGIO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -36.7% | +200.2% |
| 3 y3 years | -30.8% | -36.6% |
| 5 y5 years | +25.1% | +210.5% |
AGIO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.6% | at low | at high | +294.4% |
| 5 y | 5-year | -56.6% | +9.0% | -86.6% | +294.4% |
| alltime | all time | -56.6% | +528.6% | -86.6% | +1708.3% |
Agios Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $253.73 M(+200.2%) |
| Jun 2024 | - | $84.52 M(-28.8%) |
| Mar 2024 | - | $118.76 M(+34.6%) |
| Dec 2023 | $88.20 M(-36.7%) | $88.20 M(+37.1%) |
| Sep 2023 | - | $64.33 M(-24.1%) |
| Jun 2023 | - | $84.75 M(-18.6%) |
| Mar 2023 | - | $104.14 M(-25.2%) |
| Dec 2022 | $139.26 M(-31.4%) | $139.26 M(+13.7%) |
| Sep 2022 | - | $122.45 M(+38.3%) |
| Jun 2022 | - | $88.54 M(+10.6%) |
| Mar 2022 | - | $80.03 M(-60.6%) |
| Dec 2021 | $203.13 M(+59.4%) | $203.13 M(-49.2%) |
| Sep 2021 | - | $400.22 M(-58.7%) |
| Jun 2021 | - | $969.12 M(-48.7%) |
| Mar 2021 | - | $1.89 B(+1381.5%) |
| Dec 2020 | $127.44 M(+57.5%) | $127.44 M(+21.5%) |
| Sep 2020 | - | $104.86 M(-64.6%) |
| Jun 2020 | - | $295.86 M(+232.1%) |
| Mar 2020 | - | $89.09 M(+10.1%) |
| Dec 2019 | $80.93 M(+14.8%) | $80.93 M(-1.0%) |
| Sep 2019 | - | $81.71 M(-2.2%) |
| Jun 2019 | - | $83.58 M(-19.2%) |
| Mar 2019 | - | $103.44 M(+46.7%) |
| Dec 2018 | $70.50 M | $70.50 M(-54.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2018 | - | $156.48 M(-25.6%) |
| Jun 2018 | - | $210.32 M(-42.3%) |
| Mar 2018 | - | $364.47 M(+254.8%) |
| Dec 2017 | $102.72 M(-36.1%) | $102.72 M(-22.6%) |
| Sep 2017 | - | $132.74 M(-4.3%) |
| Jun 2017 | - | $138.72 M(-30.7%) |
| Mar 2017 | - | $200.28 M(+24.6%) |
| Dec 2016 | $160.75 M(+124.0%) | $160.75 M(-43.7%) |
| Sep 2016 | - | $285.50 M(+22.0%) |
| Jun 2016 | - | $234.05 M(+499.6%) |
| Mar 2016 | - | $39.03 M(-45.6%) |
| Dec 2015 | $71.76 M(+411.5%) | $71.76 M(-10.3%) |
| Sep 2015 | - | $80.05 M(+10.4%) |
| Jun 2015 | - | $72.53 M(+105.7%) |
| Mar 2015 | - | $35.26 M(+151.3%) |
| Dec 2014 | $14.03 M(-80.4%) | $14.03 M(-80.0%) |
| Sep 2014 | - | $70.05 M(-35.3%) |
| Jun 2014 | - | $108.25 M(+229.6%) |
| Mar 2014 | - | $32.84 M(-54.1%) |
| Dec 2013 | $71.56 M(-21.6%) | $71.56 M(-32.5%) |
| Sep 2013 | - | $106.01 M(+36.8%) |
| Jun 2013 | - | $77.48 M(-7.1%) |
| Mar 2013 | - | $83.38 M(-8.7%) |
| Dec 2012 | $91.30 M(-22.4%) | $91.30 M |
| Dec 2011 | $117.66 M | - |
FAQ
- What is Agios Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Agios Pharmaceuticals?
- What is Agios Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Agios Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Agios Pharmaceuticals?
- What is Agios Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Agios Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of AGIO is $88.20 M
What is the all time high annual cash & cash equivalents for Agios Pharmaceuticals?
Agios Pharmaceuticals all-time high annual cash & cash equivalents is $203.13 M
What is Agios Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, AGIO annual cash & cash equivalents has changed by -$51.05 M (-36.66%)
What is Agios Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AGIO is $253.73 M
What is the all time high quarterly cash and cash equivalents for Agios Pharmaceuticals?
Agios Pharmaceuticals all-time high quarterly cash and cash equivalents is $1.89 B
What is Agios Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, AGIO quarterly cash and cash equivalents has changed by +$169.21 M (+200.21%)